PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 46-51

  Milovanovic, Zorka ^a   Dzodic, R ^a   Susnjar, S ^a   Plesinac Karapandzic, V ^a   Juranic, Z ^a   Tatic, S ^b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Breast carcinoma; PTEN; Steroid receptors; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 79954515439     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dorssers LCJ, van der Flier S, Brinkman A et al. Tamoxifen resistance in breast cancer. Elucidating mechanisms. Drugs 2001; 61: 1721-1733.
2. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005; 18: 250-259. (Pubitemid 40188633)
3. Singh MN, Stringfellow HF, Paraskevaidis E, Martin-Hirsch PL, Martin FL. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 2007; 33: 91-100. (Pubitemid 46323395)
4. Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol 2005; 96: 25-31. (Pubitemid 39612413)
5. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001; 276: 9817-9824.
6. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14: 672-676. (Pubitemid 32667211)
7. Weng LP, Smith WM, Dahia PLM et al. PTEN suppresses breast cancer cell growth by phosphatase activity- dependent G1 arrest followed by cell death. Cancer Res 1999; 59: 5808-5814.
8. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002; 33: 405-409. (Pubitemid 34627590)
9. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-717.
10. Pfeiler G, Horn F, Lattrich C, Klappenberger S, Ortmann O, Treeck O. Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression. Oncol Rep 2007; 18: 1305-1309.
11. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005; 12: 599-614. (Pubitemid 41482995)
12. Waite KA, Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003; 12: 679-684. (Pubitemid 36372494)
13. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7: 548-552. (Pubitemid 32448320)
14. Garcia JM, Silva JM, Dominguez G et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57: 237-243.
15. Blanco-Aparicio C, Renner O, Leal JFM, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-1386.
16. Parsons R. Human cancer, PTEN and the PI3 kinase pathway. Semin Cell Devel Biol 2004; 15: 171-176.
17. Mills GB, Kohn E, Lu Y et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30 (Suppl 16): 93-104. (Pubitemid 37433400)
18. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007; 26: 1338-1345. (Pubitemid 46328463)
19. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-291.
20. Carroll BT, Couch FJ, Rebbeck TR, Weber BL. Polymorphisms in PTEN in breast cancer families. J Med Genet 1999; 36: 94-96. (Pubitemid 29101381)
21. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTEN less means more. Dev Biol 2004; 273: 175-184.
22. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002; 99: 63-67. (Pubitemid 34273199)
23. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003; 13: 478-483. (Pubitemid 37289398)
24. Li G, Robinson GW, Lesche R et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-4170. (Pubitemid 35012500)
25. Tokunaga E, Oki E, Kimura Y et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007; 101: 249-257. (Pubitemid 46169878)
26. Feilotter HE, Coulon V, McVeigh JL et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999; 79: 718-723. (Pubitemid 29082095)
27. Tsutsui S, Inoue H, Yasuda K et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005; 68: 398-404. (Pubitemid 41160970)
28. Brzakovic P, Jovanovic R, Pantelic M, Tomin R. Malignant breast tumors. In: Vuletic L, Nikolic S, Sobic V (Eds): Protocol for the diagnosis and treatment of malignant diseases. Institute for Oncology and Radiology, Belgrade 1985, pp 31-47 (in Serbian).
29. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
30. Perren A, Weng LP, Boag AH et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. AJP 1999; 155: 1253-1260. (Pubitemid 29488932)
31. Leake R, Barnes D, Pinder S et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 2000; 53: 634-635. (Pubitemid 30640178)
32. HercepTest™. For determination of HER2 protein overexpression. Catalog Products and Services. DAKO, 2007, 86-87.
33. Chung MJ, Jung SH, Lee BJ, Kang MJ, Lee DG. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 2004; 54: 10-15. (Pubitemid 38979576)
34. Kappes H, Goemann C, Bamberger AM, Loning T, Milde-Langosch K. PTEN expression in breast and endometrial cancer correlations with steroid hormone receptor status. Pathobiology 2001; 69: 136-142. (Pubitemid 34212084)
35. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR, Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004; 204: 93-100. (Pubitemid 39214486)
36. Menard S, Balsari A, Tagliabue E et al. On the behalf of the OMERO group. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 2008; 19: 1706-1712.